181 related articles for article (PubMed ID: 35428957)
1. Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer.
Ma X; Zhang Y; Wang C; Yu J
Clin Exp Med; 2023 Jun; 23(2):381-396. PubMed ID: 35428957
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
3. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
4. S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian NN; Wang YH; Min GT
Int J Surg; 2019 Feb; 62():34-43. PubMed ID: 30641155
[TBL] [Abstract][Full Text] [Related]
5. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
6. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials.
Zheng R; Han S; Duan C; Chen K; You Z; Jia J; Lin S; Liang L; Liu A; Long H; Wang S
Medicine (Baltimore); 2015 May; 94(17):e803. PubMed ID: 25929935
[TBL] [Abstract][Full Text] [Related]
7. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
8. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.
Shi J; Gao P; Song Y; Chen X; Li Y; Zhang C; Wang H; Wang Z
Sci Rep; 2017 Jul; 7(1):5319. PubMed ID: 28706257
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials.
Huang Q; Mei Z; Han X
Front Oncol; 2022; 12():972767. PubMed ID: 36119468
[TBL] [Abstract][Full Text] [Related]
11. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis.
Yang J; Zhou Y; Min K; Yao Q; Xu CN
World J Gastroenterol; 2014 Sep; 20(33):11886-93. PubMed ID: 25206296
[TBL] [Abstract][Full Text] [Related]
12. Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials.
Zhang Y; Ma B; Huang XT; Li YS; Wang Y; Liu ZL
Medicine (Baltimore); 2016 Feb; 95(8):e2792. PubMed ID: 26937908
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.
Guo X; Yang B; He L; Sun Y; Song Y; Qu X
Front Immunol; 2022; 13():905651. PubMed ID: 36003374
[TBL] [Abstract][Full Text] [Related]
15. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
16. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
18. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H
Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257
[TBL] [Abstract][Full Text] [Related]
19. Second-line Chemotherapy in Advanced Gastric Cancer: Taxanes versus 5-FU-Based Treatment.
Duzkopru Y; Cilbir E; Imamoglu GI; Dogan O; Eren T
J Coll Physicians Surg Pak; 2023 Jul; 33(7):770-774. PubMed ID: 37401218
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
